Piramal Pharma Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Piramal Pharma Ltd. from all sources in a single place.

Piramal Pharma Ltd.

01 Apr 2025

219.83

5.50%

Company Update

Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The Securities And Exchange Board …

BSE India

Disclosure under Regulation 30 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) regulations, 2015 ("SEBI Listing Regaultions")

pdf

Piramal Pharma Ltd.

21 Mar 2025

219.83

5.50%

AGM

Piramal Pharma Ltd - 543635 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

BSE India

E-voting Results and Scrutinizers Report on Postal Ballot

pdf

Piramal Pharma Ltd.

20 Mar 2025

219.83

5.50%

Piramal Pharma arm, Irish firm get UKMHRA approval for Neoatricon in UK

Business Standard

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a medication used in the treatment of low blood pressure and low heart rate in children. Piramal Critical Care (PCC) has secured the commercialisation rights for Neoatricon, the first paediatric strength solution for infusion of Dopamine Hydrochloride, for the EU, the UK, and Norway markets, Piramal Pharma said in a regulatory filing. PCC would be responsible for distributing Neoatricon in these regions, it added. Developed by BrePco Biopharma, Neoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of Dopamine Hydrochloride. It is available in a concentration of 1.5mg/mL in a 30 mL vial and a higher strength containing 4.5mg/mL in a 50 mL vial. Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or ..

Piramal Pharma Ltd. is trading above its 200 day SMA of 218.2

Piramal Pharma Ltd.

20 Mar 2025

219.83

5.50%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release - Piramal Critical Care and BrePco announces MHRA approval for Neoatricon in the UK.

pdf

Piramal Pharma Ltd.

11 Mar 2025

219.83

5.50%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Piramal Pharma Ltd.

20 Feb 2025

219.83

5.50%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Submission of copy of newspaper advertsiment for Postal Ballot Notice

pdf

Piramal Pharma Ltd.

19 Feb 2025

219.83

5.50%

AGM

Piramal Pharma Ltd - 543635 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

BSE India

Submission of Postal Ballot Notice & Intimation of Remote E-Voting

pdf

Piramal Pharma Ltd.

18 Feb 2025

219.83

5.50%

Company Update

Piramal Pharma Ltd - 543635 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Intimation under Regulation 30 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regualtions") - US FDA Inspection at Piramal Pharma''s facility located at Turbhe.

pdf